)
)
)
RESTEM is a leading clinical-stage biotechnology company focused on developing off-the-shelf, next-generation cell therapies for autoimmune, inflammatory, and age-related diseases. Leveraging proprietary products, deep clinical expertise, and advanced manufacturing capabilities, RESTEM is advancing two potentially transformative programs, Restem-L, our umbilical cord lining progenitor cells (UMPCs) therapy for autoimmune diseases, and activated natural killer cell (aNK) therapeutics targeting senescence and age-associated disorders. Our therapies are designed to reprogram the immune system rather than focusing solely on symptom management, offering patients with limited options the potential to address underlying disease mechanisms. RESTEM is headquartered in Miami, Florida. For more information, please visit www.restem.com and follow us on X and LinkedIn.
Year Founded
2018
Next catalyst (value inflection) update
Phase 2 data readout for IIM
Expected time of next catalyst update
Dec-26
City
Miami
Country
United States
Company CEO or top company official
Andres Isaias
Development Phase of Primary Product
Phase II
Lead Product in Development
Restem-L in Phase 2/3 clinical trial for Idiophatic Inflammatory Myopathy
Number of Unlicensed Products
3
Therapeutic Area
Immunology
Website
https://www.restem.com/
){kind=logo}
)
)
){kind=logo}
)
){kind=logo}
){kind=logo}
){kind=logo}
